Observational studyCancer reports (Hoboken, N.J.)2025
Endoscopic Ultrasound-Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment.
Observational study in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endoscopic Ultrasound-Guided Tissue Acquisition for Breast Cancer Liver Metastases Enables the Detection of Biomarkers Essential for Treatment.Cancer reports (Hoboken, N.J.) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. Since biomarker expression may differ between primary and metastatic lesions, biopsy of metastatic sites is recommended whenever feasible. The liver is a common metastatic site for breast cancer, and percutaneous biopsy has traditionally been the standard approach. Recently, endoscopic ultrasound-guided tissue acquisition (EUS-TA) has emerged as an alternative method for sampling focal liver lesions. However, the utility of EUS-TA in assessing breast cancer biomarkers remains unclear.
aimTo evaluate the diagnostic performance of EUS-TA, including its ability to assess biomarkers in liver metastases from breast cancer.
methodsThis single-center, retrospective observational study included patients who underwent EUS-TA for breast cancer liver metastases between 2016 and 2023. Clinical characteristics and specimen adequacy were analyzed. A pathologist classified the obtained tissue samples into four categories: (A) insufficient for diagnosis, (B) diagnosis possible only at the cytology level, (C) histological evaluation possible, but additional immunostaining for biomarkers not feasible, and (D) histological evaluation and additional immunostaining for biomarkers feasible.
resultsFifteen cases were included, with a median patient age of 68 years (all female). The median liver lesion size was 20 mm (range: 8-50 mm). The lesions were located in the left lobe in 12 cases and the right lobe in 3 cases. A 22G needle was used in 14 cases, while a 25G needle was used in 1 case. Specimen adequacy was classified as follows: category A in 1 case (6.6%), B in 2 cases (13.3%), C in 0 cases (0%), and D in 12 cases (80%). Biomarker evaluation was feasible in the majority of cases. No procedure-related adverse events were observed.
conclusionEUS-TA is a valuable method for obtaining tissue samples from breast cancer liver metastases, enabling biomarker assessment in most cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.